Bioequivalence and Bioavailability Forum 05:52 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Dabigatran EMA - product-specific guide [Regulatives / Guidelines]

posted by nobody - 2019-02-14 13:34  - Posting: # 19918
Views: 209

» Highly variable in fasted but not in fed state.

Hm, here we talk about solubility over relevant pH range. Only good solubility in acidic range, but... see Samant, 2018 on ribociclib. Solubility in aqueous media is only half the story.

» Aren’t you notoriously shouting “It’s the originator, stupid…”?

Could you elaborate on this. No clue what this might mean. If you want a duel, choose your weapon
:hungry:

» I’m more concerned about the first footnote in the guidance

* As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of Cmax. If high intra-individual variability (CVintra > 30 %) is expected, the applicants might follow respective guideline recommendations.

meaning that one can plan for the EMA’s method of reference-scaling. Was the EMA’s PKWP not aware of the the FDA’s guidance?

Narrow therapeutic range... maybe in the USA. In the EU there are no mass tort trials...

What buys you the widening for Cmax, when both parameters are highly variable? :confused:

Kindest regards, nobody

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,188 posts in 4,084 threads, 1,308 registered users;
online 8 (0 registered, 8 guests [including 7 identified bots]).

The aim of science is not to open the door to infinite wisdom,
but to set a limit to infinite error.    Bertolt Brecht

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed